First Human Trial of Myelin Peptide-Coupled Cell Therapy for Multiple Sclerosis

Open-label, single-center, dose-escalation phase 1 trial. Nine MS patients (7 relapsing-remitting, 2 secondary progressive) off standard therapies received a single intravenous infusion of their own blood cells chemically coupled with seven myelin peptides. Safety, tolerability, and immune responses were monitored through neurological exams, MRI, laboratory tests, and immunological assessments.

Current MS treatments broadly suppress the immune system, which controls the disease but leaves patients vulnerable to infections and cancers. Antigen-specific tolerance — teaching the immune system to stop attacking just the myelin targets — would be a paradigm shift, treating the root cause while leaving the rest of immunity intact. This trial is the first demonstration that this approach is feasible and safe in human MS patients.

This trial is part of a broader effort to develop antigen-specific immunotherapy for autoimmune diseases. The concept — using peptide-coupled cells to induce tolerance — was proven in animal models of MS decades ago and this was the critical first step into humans. If effective in larger trials, this approach could potentially apply not just to MS but to other autoimmune conditions like type 1 diabetes, where the immune targets are known.

Phase 1 safety trial only; n=9; no control group; open-label; single center; patients off standard therapy; clinical efficacy not assessed; long-term durability unknown.